Comparison of "framework Shuffling" and "CDR Grafting" in Humanization of a PD-1 Murine Antibody

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jul 30

PMID 39076979

Authors

Yongmei Wang

Yi-Li Chen

Hui Xu

Gul E Rana

Xiaorong Tan

Mengying He

Qingqing Jing

Qi Wang

Guifeng Wang

Zuoquan Xie

Chunhe Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Humanization is typically adopted to reduce the immunogenicity of murine antibodies generated by hybridoma technology when used in humans.

Methods: Two different strategies of antibody humanization are popularly employed, including "complementarity determining region (CDR) grafting" and "framework (FR) shuffling" to humanize a murine antibody against human programmed death-1 (PD-1), XM PD1. In CDR-grafting humanization, the CDRs of XM PD-1, were grafted into the human FR regions with high homology to the murine FR counterparts, and back mutations of key residues were performed to retain the antigen-binding affinities. While in FR-shuffling humanization, a combinatorial library of the six murine CDRs in-frame of XM PD-1 was constructed to a pool of human germline FRs for high-throughput screening for the most favorable variants. We evaluated many aspects which were important during antibody development of the molecules obtained by the two methods, including antibody purity, thermal stability, binding efficacy, predicted humanness, and immunogenicity, along with T cell epitope prediction for the humanized antibodies.

Results: While the ideal molecule was not achieved through CDR grafting in this particular instance, FR-shuffling proved successful in identifying a suitable candidate. The study highlights FR-shuffling as an effective complementary approach that potentially increases the success rate of antibody humanization. It is particularly noted for its accessibility to those with a biological rather than a computational background.

Discussion: The insights from this comparison are intended to assist other researchers in selecting appropriate humanization strategies for drug development, contributing to broader application and understanding in the field.

References

Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A . Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011; 63(6):325-35. PMC: 3626422. DOI: 10.1007/s00251-011-0513-0. View

Wu H, An L . Tailoring kinetics of antibodies using focused combinatorial libraries. Methods Mol Biol. 2002; 207:213-33. DOI: 10.1385/1-59259-334-8:213. View

Mehta S, Bee J, Randolph T, Carpenter J . Partial unfolding of a monoclonal antibody: role of a single domain in driving protein aggregation. Biochemistry. 2014; 53(20):3367-77. DOI: 10.1021/bi5002163. View

Abbas A, Linman M, Cheng Q . New trends in instrumental design for surface plasmon resonance-based biosensors. Biosens Bioelectron. 2010; 26(5):1815-24. PMC: 3014383. DOI: 10.1016/j.bios.2010.09.030. View

Damschroder M, Widjaja L, Gill P, Krasnoperov V, Jiang W, DallAcqua W . Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol. 2007; 44(11):3049-60. DOI: 10.1016/j.molimm.2006.12.019. View

Bai Z, Xu M, Mei Y, Hu T, Zhang P, Chen M . Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines. 2021; 9(12). PMC: 8698692. DOI: 10.3390/biomedicines9121783. View

Ahmadzadeh V, Farajnia S, Feizi M, Nejad R . Antibody humanization methods for development of therapeutic applications. Monoclon Antib Immunodiagn Immunother. 2014; 33(2):67-73. DOI: 10.1089/mab.2013.0080. View

DallAcqua W, Damschroder M, Zhang J, Woods R, Widjaja L, Yu J . Antibody humanization by framework shuffling. Methods. 2005; 36(1):43-60. DOI: 10.1016/j.ymeth.2005.01.005. View

Wu H . Simultaneous humanization and affinity optimization of monoclonal antibodies. Methods Mol Biol. 2002; 207:197-212. DOI: 10.1385/1-59259-334-8:197. View

10.

Leem J, Dunbar J, Georges G, Shi J, Deane C . ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation. MAbs. 2016; 8(7):1259-1268. PMC: 5058620. DOI: 10.1080/19420862.2016.1205773. View

11.

Abanades B, Wong W, Boyles F, Georges G, Bujotzek A, Deane C . ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins. Commun Biol. 2023; 6(1):575. PMC: 10227038. DOI: 10.1038/s42003-023-04927-7. View

12.

Izadi S, Anandakrishnan R, Onufriev A . Building Water Models: A Different Approach. J Phys Chem Lett. 2014; 5(21):3863-3871. PMC: 4226301. DOI: 10.1021/jz501780a. View

13.

Verhoeyen M, Milstein C, Winter G . Reshaping human antibodies: grafting an antilysozyme activity. Science. 1988; 239(4847):1534-6. DOI: 10.1126/science.2451287. View

14.

Mu S, Liang Z, Wang Y, Chu W, Chen Y, Wang Q . PD-L1/TIGIT bispecific antibody showed survival advantage in animal model. Clin Transl Med. 2022; 12(5):e754. PMC: 9076010. DOI: 10.1002/ctm2.754. View

15.

Reynisson B, Barra C, Kaabinejadian S, Hildebrand W, Peters B, Nielsen M . Improved Prediction of MHC II Antigen Presentation through Integration and Motif Deconvolution of Mass Spectrometry MHC Eluted Ligand Data. J Proteome Res. 2020; 19(6):2304-2315. DOI: 10.1021/acs.jproteome.9b00874. View

16.

Foote J, Winter G . Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol. 1992; 224(2):487-99. DOI: 10.1016/0022-2836(92)91010-m. View

17.

Hwang W, Foote J . Immunogenicity of engineered antibodies. Methods. 2005; 36(1):3-10. DOI: 10.1016/j.ymeth.2005.01.001. View

18.

Riechmann L, Clark M, Waldmann H, Winter G . Reshaping human antibodies for therapy. Nature. 1988; 332(6162):323-7. DOI: 10.1038/332323a0. View

19.

Braun A, Kwee L, Labow M, Alsenz J . Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res. 1997; 14(10):1472-8. DOI: 10.1023/a:1012193326789. View

20.

Lazar G, Desjarlais J, Jacinto J, Karki S, Hammond P . A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol. 2006; 44(8):1986-98. DOI: 10.1016/j.molimm.2006.09.029. View